Drug Profile
Research programme: chemotherapeutic drugs - Tydock Pharma
Latest Information Update: 28 Mar 2020
Price :
$50
*
At a glance
- Originator Tydock Pharma
- Class Antineoplastics
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Mar 2020 No recent reports of development identified for research development in Cancer in Italy
- 23 Feb 2016 Early research in Cancer in Italy (unspecified route)